Ohr Pharmaceutical Inc 4
4 · Ohr Pharmaceutical Inc · Filed Apr 13, 2017
Insider Transaction Report
Form 4
Slakter Jason Scott
Director
Transactions
- Purchase
Common Stock, par value $0.0001 per share
2017-04-10$0.70/sh+142,858$100,001→ 1,067,898 total - Purchase
Warrants (right to buy)
2017-04-10+100,001→ 100,001 totalExercise: $1.00From: 2017-04-10Exp: 2022-04-10→ Common Stock (100,001 underlying)
Holdings
- 1,195,724(indirect: By LLC)
Common Stock, par value $0.0001 per share
Footnotes (2)
- [F1]On April 5, 2017, Ohr Pharmaceutical, Inc. (the "Issuer") entered into a securities purchase agreement (the "Securities Purchase Agreement") with various purchasers set forth on the signatures pages thereto, including the Reporting Person. Pursuant to the Securities Purchase Agreement, the Reporting Person purchased shares of the Issuer's common stock (the "Common Stock") and warrants to purchase shares of Common Stock in a registered offering (the "Offering") for an aggregate purchase price of $100,000.06. The closing of the Offering occurred on April 10, 2017.
- [F2]SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestones 1 and 2 have been met and the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC on each of December 15, 2015 and July 18, 2016. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.